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be interpreted in terms of the variations of its two determinants
(HR and SV). In some cases, the absence of increase in CO in re-
sponse to fluid infusion may not indicate the absence of
effect. Monitoring SV may provide more reliable information
concerning the effect of fluid infusion. It may be preferable to
use a definition of fluid responsiveness based on SV variation
in studies testing the ability of an indicator to predict fluid
responsiveness.
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Efficacy of dexmedetomidine compared
with midazolam for sedation in adult
intensive care patients
Editor—In a recently published article,1 Dr Adams and collea-
gues review, among others, two of our studies addressing dex-
medetomidine for sedation in critically ill patients.2 3 While we
agree with their overall conclusion that ‘so far the evidence of
advantages of dexmedetomidine in the ICU setting remains
limited’, we would like to address some of their criticism of
our studies.
Dr Adams and colleagues mention that we did not find
statistically significant differences in sedation between midazo-
lam and dexmedetomidine treatment groups. We believe that
they have missed important aspects of our study design:3 our
main interest was to assess the effect of the sedative drugs on
length of mechanical ventilation, with the prerequisite that dex-
medetomidine is not inferior to midazolam (and propofol) in
maintaining the target sedation. We therefore used two hierar-
chial co-primaryendpoints—first, assessing non-inferiority, and
then comparing the effect on duration of mechanical ventila-
tion. Only if the non-inferiority was confirmed, could the effect
on mechanical ventilation be assessed. Non-inferiority designs
have not been used before in assessing any current sedative
drugs:ourdesignrequestingproofofnon-inferiority inmaintain-
ing sedation before testing the hypothesis of shorter mechanic-
al ventilation should be considered more rigorous compared
with the conventional designs showing ‘no difference’. We also
tested the secondary outcome variables with the prerequisite
that dexmedetomidine sedation was non-inferior (or at least
as good) as sedation with the standard drug—something that
has not been shown for any prior sedative.
Further, the authors state that ‘The main problem with
assessing the effectiveness of sedation is that most measure-
ments are made from subjective scales and that only one
Table 1 Comparison of a hemodynamic parameters between the
responders, non-responders, and discordant groups. Values are
expressed as mean (standard deviation) or mean (CI95%). CO,
cardiac output; MAP, mean arterial pressure; HR, heart rate; SV,
stroke volume; DrespSV, respiratory stroke volume variation.
Data were compared using ANOVA with the post hoc Bonferonni test.
aP,0.05 non-responder vs responder. bP,0.05 non-responder vs
discordant. cP,0.05 responder vs discordant. *P,0.05 between
baseline and volume expansion
Non-
responders
(n558)
Responders to
SVand CO
(n564)
Discordant
(n516)
HR (beats min21)
Baseline 67 (18) 67 (17) 78 (18)b,c
Volume
expansion
66 (17) 69 (17) 68 (12)*
MAP (mm Hg)
Baseline 75 (13) 76 (12) 74 (15)
Volume
expansion
77 (15) 81 (14)* 77 (13)
SV (ml)
Baseline 84 (20) 69 (16)a 72 (19)b
Volume
expansion
87 (22)* 91 (20)* 88 (22)*
CO (ml min21)
Baseline 5.5 (1.9) 4.5 (1.2)a 5.5 (1.5)c
Volume
expansion
5.6 (1.9) 6.3 (2)* 6 (1.7)*
DrespSV (%)
Baseline 11 (5) 21 (9)a 26 (10)c
Volume
expansion
10 (4) 11 (6)* 15 (11)*,b,c
Variation of
HR with
volume
expansion (%)
21 (24; 2) 3 (0; 6) 211 (217; 26)b,c
Variation of SV
with volume
expansion (%)
3 (1; 6) 34 (28; 40)a 20 (17; 24)b,c
Variation of
CO with
volume
expansion (%)
2 (22; 5) 38 (32; 44)a 6 (0; 12)c
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study4 included BIS as an objective measurement’. We find this
statement misleading. BIS has never been adequately
validated for monitoring sedation in the ICU. We and others
have demonstrated the major problems associated with
BIS-guided sedation at light to moderate sedation levels.5 6
In contrast, standard sedation assessment with RASS has
been validated.7 While the proposal of Adams and colleagues
that all assessments should have been performed by the
same blinded investigator is scientifically correct, this is a
highly unrealistic suggestion for a multi-centre study including
1000 patients and 2-hourly sedation assessments.
We believe that there are other inaccuracies of important
features in their critique of our studies. The claim that we did
not report blinding of RASS assessors is incorrect: we described
the double-blinded, double-dummy design, where sedatives
and dummys were prepared, connected, and removed by inde-
pendent personnel, so that those making the RASS assess-
ments were indeed blinded to the treatment (Methods
section, paragraph ‘randomization and masking’). Adams
and colleagues also comment that patients who received or
did not receive rescue sedation were not independently ana-
lysed. In both PRODEX and MIDEX trials,3 almost 50% of the
patients needed rescue sedation at some time point (Table 2
of the original manuscript). In the study by Ruokonen and col-
leagues,2 the percentage was close to 80% in each group (Elec-
tronic supplement, paragraph ‘rescue medication’). The result
of analysing the primary outcome separately in only those
patients who could be sedated by the study drug alone would
be of little clinical significance. We do not agree that omitting
such an analysis ‘leads to difficulties in accurately interpreting
the conclusions’.
Finally, Adams and colleagues claim that there are numer-
ical inconsistencies with respect to total number of excluded
patients, and of patients with treatment withdrawal. We are
surprised by this claim, especially since we have explained
this to the authors in response to their direct correspondence
with us: the total numbers are smaller than the sum of all
reasons since several reasons could simultaneously apply, as
clearly mentioned in the legend to Figure 1 of the original
manuscript.3 The ‘inconsistency’ in the number of patients
with serious adverse events in the article by Ruokonen and col-
leagues2 relates to mix-up of ‘numbers of SAE’ and ‘patients
with SAE’: the correct numbers of SAE and patients with SAE
are found in the electronic supplement of the manuscript by
Ruokonen and colleagues.
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Reply from the author
Editor—Thank you for the opportunity to respond to the letter
of Jakob and colleagues which was written regarding a recent
review published in theBritish Journal of Anaesthesia.1 I should
say at the outset that we accept that Jakob and colleagues
have performed the best designed trials in this area and apolo-
gize if the article gave the impression that this was not the case.
On the subject of non-inferiority trials, I am afraid we are
going to have to agree to disagree. I acknowledge that there
is a problem facing clinical research in that trials are increa-
singly being required to show benefits on clinically meaningful
endpoints rather than surrogate endpoints (e.g. biochemical).
This has resulted in investigators using an ‘equivalence’ or
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